No. of depression patients exceeds 1m in 2022
Seoul subway fare to rise 12% beginning Saturday
Korean Air to submit new merger plan to ease antitrust concerns
Korea to begin experiment with central bank digital currency
Races tighten in Seoul as parties battle for Assembly control
6-year-old Uzbek girl found dead in Daegu
Star lecturers, hagwon probed over buying Suneung questions
Culture minister nominee warns celebrities to be cautious over political speech
US House votes to remove Speaker Kevin McCarthy
Actor Park Eun-bin opens 28th Busan International Film Festival’s opening ceremony
Celltrion, Rani team up to develop oral Humira biosimilar for arthritisBy Shim Woo-hyun
Published : June 5, 2023 - 16:33
South Korea's biopharmaceutical company Celltrion announced Monday that the company will cooperate with the US biotech firm Rani Therapeutics to develop an oral version of the Humira biosimilar CT-P17.
CT-P17, also known as Yuflyma, is a high-concentration, low-volume and citrate-free biosimilar of Humira, an injectable treatment for rheumatoid arthritis and other autoimmune conditions, developed by AbbVie. Celltrion received the US Food and Drug Administration's approval for the injectable adalimumab biosimilar in May, as well as the European Medicines Agency approval in 2021.
To co-develop the oral formulation of the Humira biosimilar, named RT-105, Celltrion signed a contract with Rani Therapeutics, the same company Celltrion signed another contract in January to develop RT-111, an oral formulation of Celltrion's Stelara biosimilar CT-P43.
"Celltrion expects the latest collaboration with Rani will help the company increase its footing in the adalimumab market," an official from Celltrion said. The adalimumab market is currently estimated at around $21.2 billion, with over 87 percent ($18.62 billion) of the sales coming from the US, Celltrion added.
Under the contract, Celltrion will supply Rani with CT-P17 required for the development of the oral version of the biosimilar.
In the future, Celltrion can have priority negotiation rights for global development and sales of the oral adalimumab biosimilar, depending on the results of the phase 1 clinical trials for the oral formulation.
S. Korea, US closely monitoring N. Korea for signs of nuclear reactor halt
S. Korea, Japan to hold 'strategic dialogue' amid warming ties
PM orders measures to prevent public opinion manipulation on web portals